News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
AstraZeneca PLC Puts up a Fight Against Scottish Medicines Consortium’s Iressa Rejection
May 13, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- AstraZeneca’s cancer drug Iressa has suffered a further setback in the UK after cost regulators rejected its use on NHS Scotland as a treatment for patients with non-small cell lung cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Vaccines
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint
March 23, 2026
·
2 min read
·
Heather McKenzie
Insights
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
March 23, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Spinal muscular atrophy
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
March 20, 2026
·
2 min read
·
Tristan Manalac
FDA
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
March 19, 2026
·
2 min read
·
Annalee Armstrong
